SCHEMBL352038

SCHEMBL352038

Cc1cccc2c(CCC(=O)O)cn(S(=O)(=O)c3cccc(-c4ccc(OC(F)(F)F)cc4)c3)c12

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 5/20 0.48
PPARG P37231 4/20 0.48
PPARA Q07869 4/20 0.48
RORC P51449 4/20 0.47
PLA2G4A P47712 1/20 0.40
FFAR1 O14842 3/20 0.39
FFAR4 Q5NUL3 3/20 0.39
HTR6 P50406 3/20 0.39
MME P08473 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL349716 0.90 RORC (0.47) PPARDPPARGPPARARORCPLA2G4A
SCHEMBL351598 0.89 RORC (0.51) PPARDPPARGPPARARORCHTR6
SCHEMBL352527 0.87 RORC (0.55) PPARDPPARGPPARARORCPLA2G4A
SCHEMBL350737 0.84 PPARG (0.67) PPARDPPARGPPARARORCHTR6
SCHEMBL352713 0.83 RORC (0.54) PPARDPPARGPPARARORCPLA2G4A
SCHEMBL351336 0.82 PPARG (0.53) PPARDPPARGPPARARORCPLA2G4A
SCHEMBL351443 0.80 RORC (0.57) PPARDPPARGPPARARORCPLA2G4A
SCHEMBL349738 0.79 PPARG (0.66) PPARDPPARGPPARARORCHTR6
SCHEMBL3036653 0.79 PPARG (0.66) PPARDPPARGPPARAHTR6
SCHEMBL350222 0.78 RORC (0.51) PPARDPPARGPPARARORCHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015966-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON INC 2012-01-19 US disclosed
US-20120015966-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON INC 2012-01-19 US disclosed
US-20120015966-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON INC 2012-01-19 US disclosed
US-8053463-B2 e.g. {3-butoxy-5-[4-(4-trifluoromethoxy-phenoxy)-benzenesulfonyl]-phenyl}-acetic acid; peroxisome proliferator activated receptor modulator; antidiabetic agent; obesity, hyperlipidemia, dyslipidemia, hypertriglyceridemia, Syndrome X, insulin resistance, diabetic neuropathy, atherosclerosis, eczema PLEXXIKON INC. (US) 2011-11-08 US disclosed
US-8053463-B2 e.g. {3-butoxy-5-[4-(4-trifluoromethoxy-phenoxy)-benzenesulfonyl]-phenyl}-acetic acid; peroxisome proliferator activated receptor modulator; antidiabetic agent; obesity, hyperlipidemia, dyslipidemia, hypertriglyceridemia, Syndrome X, insulin resistance, diabetic neuropathy, atherosclerosis, eczema PLEXXIKON INC. (US) 2011-11-08 US disclosed
EP-2114879-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2009-11-11 EP disclosed
US-20080255201-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON INC 2008-10-16 US disclosed
US-20080255201-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON INC 2008-10-16 US disclosed
WO-2008109700-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015966-A1 PPAR ACTIVE COMPOUNDS PPARG, PPARA, PPARD PPARD 3/4885PPARG 1/4885PPARA 2/4885
US-20080255201-A1 PPAR ACTIVE COMPOUNDS PPARG, PPARA, PPARD PPARD 3/4885PPARG 1/4885PPARA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.